Identification of biomarkers and candidate inhibitors for multiple myeloma

Hanming Gu^{1,2}, Wei Wang³, Gongsheng Yuan^{4*}

¹School of Electronic, Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai, China

²SHU-UTS SILC Business School, Shanghai University, Shanghai, China

³Shanghai Civil Aviation College, Shanghai, China

⁴Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University, Shanghai, China

*Corresponding author: Dr. Gongsheng Yuan, Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University, Shanghai, China
gsyuan14@gmail.com

Abstract

Multiple myeloma (MM) is a plasma cell malignancy that causes the overabundance of monoclonal paraprotein (M protein) and organ damages. In our study, we aim to identify biological markers and processes of MM using a bioinformatics method to elucidate their potential pathogenesis. The gene expression profiles of the GSE153626 datasets were originally produced by using the high-throughput Illumina HiSeq 4000 (Mus musculus). The functional categories and biochemical pathways were identified and analyzed by the Kyoto Encyclopedia of Genes and Genomes pathway (KEGG), Gene Ontology (GO), and Reactom enrichment. KEGG and GO results showed the biological pathways related to immune dysfunction and signal transduction are mostly affected in the development of MM. Moreover, we identified several genes including Gngt2, Foxp3, and Cd3g were involved in the regulation of immune cells. We further predicted new inhibitors that have the ability to block the progression of MM based on the L1000fwd analysis. Therefore, this study provides further insights into the underlying pathogenesis of MM.

Introduction

Multiple myeloma is hematological cancer that caused end-organ damage including anemia, renal impairment, and bone lesions¹. MM primarily occurs in the elderly (over 65 years) and the global incidence has increased dramatically since 1990^{2, 3}. With current chemotherapy and regimens, the survival rate has improved, although it is still a high-risk disease⁴. Malignant migration of MM is a consequence of a combination of factors such as genetic mutations and genetic evolutions in the BM environment⁵. Moreover, immune dysfunction was found in myeloma patients, raising the question of whether immunological dysregulation is an important mechanism of disease development^{6, 7}.

Most of the findings showed that several types of mouse models have been used, which aim to provide insights on the relationship between MM and BM microenvironment⁸. Here, the mouse model we analyzed was created through conditionally activating the endogenous NrasQ61R and an MYC transgene in germinal center B cells⁹. This mouse model developed a classic malignant MM characterized by phenotype, signaling

pathways, and MM gene signatures⁹. Recent studies suggest that the uncontrolled immunological microenvironment leads to the progress of MM¹⁰. The activated MM may cause bone damage, anemia, multiple organ metastasis¹¹. However, the mechanism underlying MM is still unknown.

Here, we studied the relative changes of genes in MM mouse models. Then, we identified and analyzed a series of DEGs, the relevant biological process, and potential drug targets of MM using comprehensive bioinformatic analysis. Last, we performed the gene and pathway analysis, the functional enrichment, and protein-protein interaction (PPI) for discovering MM gene nodes. The critical genes and pathways could be in favor of future clinical and therapeutic studies.

Methods

Data resources

The dataset GSE153626 was downloaded from the GEO database (<http://www.ncbi.nlm.nih.gov/geo/>). The data was produced by Illumina HiSeq 4000 (Mus musculus), Blood Research Institute, Versiti 8727 W Watertown Plank Rd, Milwaukee, Wisconsin. Bulk RNA-Seq analysis was performed using CD138+ B220-CD45.2+ bone marrow cells of three control and five MM models conditionally activating expression of endogenous NrasQ61R and a MYC transgene in germinal center B cells (VQ mice).

Data acquisition and preprocessing

The dataset GSE153626 containing WT samples and VQ mice samples was analyzed and conducted by R script as described previously^{12, 13}. We used a classical t test to identify DEGs with $P < .01$ and fold change ≥ 1.5 as being statistically significant.

Gene functional analysis

Gene ontology (GO) analysis is a widely used approach to develop a comprehensive and computational model of biological systems to analyze genomic data and define characteristic biological information¹⁴. The Kyoto Encyclopedia of Genes and Genomes (KEGG) database is commonly used for understanding high-level functions and utilities

of the biological system¹⁵. We performed the GO analysis and KEGG pathway enrichment analysis by using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) (<http://david.ncifcrf.gov/>) as described previously^{16, 17}. $P < .05$ and gene counts > 10 were considered statistically significant.

Module analysis

The Molecular Complex Detection (MCODE) of cytoscape software was used to analyze the densely connected regions in protein-protein interaction (PPI) networks¹⁸. The significant modules were from the constructed PPI network using MCODE¹⁹. The function and pathway enrichment analyses were performed by using DAVID, and $P < .05$ was used as the cutoff criterion.

Reactome pathway analysis

The dataset was performed by the Reactome pathway (<https://reactome.org/>) to obtain the visualization, interpretation and analysis of potential pathways. $P < .05$ was considered statistically significant.

Results

Identification of DEGs in myeloma cells from MM models

Multiple myeloma mouse models were created by activating the expression of endogenous NrasQ61R and a MYC transgene in germinal center B cells (VQ mice) at Blood Research Institute, Versiti (Wisconsin, USA). To gain the insights on MM model genes, the modular transcriptional signature of VQ mice was compared to that of WT mice. A total of 3721 genes were identified to be differentially expressed in MM models with the threshold of $P < 0.005$. The top 10 up- and down-regulated genes for VQ mice and WT control samples are listed in Table 1.

KEGG analysis of DEGs in MM models

To further identify the biological roles and potential mechanisms of the DEGs from the MM models versus WT controls, we performed KEGG pathway and GO categories enrichment analysis (Supplemental Table S1). KEGG pathways

(<http://www.genome.jp/kegg/>) are a collection of manually drawn pathway maps for understanding the molecular interaction, reaction and relation networks. Our study presented the top ten enriched KEGG pathways including “Inflammatory bowel disease (IBD)”, “Hematopoietic cell lineage”, “African trypanosomiasis”, “Transcriptional misregulation in cancer”, “Pancreatic secretion”, “Fc epsilon RI signaling pathway”, “T cell receptor signaling pathway”, “Natural killer cell mediated cytotoxicity”, “Salivary secretion”, and “Oxytocin signaling pathway” (Figure 1).

GO analysis of DEGs in MM models

Gene ontology (GO) analysis is a system for hierarchically classifying genes, which includes cellular components (CC), molecular functions (MF), and biological processes (BP)²⁰. Here, we identified top ten cellular components including “Membrane”, “External side of plasma membrane”, “Cell surface”, “Plasma membrane”, “Cell-cell junction”, “Mast cell granule”, “Extracellular exosome”, “Cytoplasmic side of plasma membrane”, “Early endosome”, and “Integral component of membrane” (Figure 1). We then identified top ten biological processes: “Negative regulation of interleukin-10 production”, “Positive regulation of Rho protein signal transduction”, “Myeloid cell differentiation”, “Negative regulation of T cell proliferation”, “B cell activation”, “Positive regulation of T cell proliferation”, “Immune system process”, “Adaptive immune response”, “Immune response”, and “Positive regulation of gene expression” (Figure 1). Last, we identified top ten molecular functions: “Protein binding”, “Receptor activity”, “Guanyl-nucleotide exchange factor activity”, “Cysteine-type endopeptidase inhibitor activity involved in apoptotic process”, “ATPase binding”, “Semaphorin receptor activity”, “Transcription regulatory region DNA binding”, “Phosphoprotein phosphatase activity”, “Actin binding”, and “Signal transducer activity” (Figure 1).

PPI network and Module analysis

The PPI networks were created to analyze the relationships of DGEs at the protein level^{21, 22}. The criterion of combined score >0.7 was chosen and the PPI network was constructed by using the 143 nodes and 209 interactions. Among these nodes, the top ten genes with highest scores are shown in Table 2. The top two significant modules of

MM models versus WT samples were selected to indicate the functional annotation (Figure 2).

Reactome Pathway in MM models

We identified several signaling pathways by using Reactome Pathway Database (<https://reactome.org/>). We identified top ten signaling pathways including: “Interleukin-35 Signalling”, “RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)”, “Other semaphorin interactions”, “TFAP2 (AP-2) family regulates transcription of growth factors and their receptors”, “Interleukin-18 signaling”, “Neurophilin interactions with VEGF and VEGFR”, “Defective factor IX causes hemophilia B”, “Interleukin-12 family signaling”, “Interleukin-38 signaling”, and “RUNX1 regulates transcription of genes involved in BCR signaling” (Supplemental Table S2). We then constructed the reaction map according to the signaling pathways (Figure 3).

Potential inhibitors in MM models

To further know how to prevent the MM, we introduced the L1000FDW system that can predict and analyze the potential inhibitors (Figure 4). With the mechanisms-of-action (MOA), the L1000FDW system indicated the most potentially affected pathways. We selected top ten inhibitors according to the DEGs and the inhibitor maps: “BRD-A47816767”, “radicicol”, “melperone”, “IKK-2-inhibitor-V”, “I-606051”, “alitretinoin”, “BRD-K70771662”, “SSR-69071”, “SA-1447005”, and “CAY-10470” (Supplemental Table S3).

Discussion

MM is a plasma cell malignancy that accounts for about 10% of hematologic cancers²³. MM causes several symptoms such as organ damage, anemia and lytic bony lesions²⁴. MM was triggered from a premalignant state called "monoclonal gammopathy of undetermined significance (MGUS)"²⁵. Malignant transformation is the result of combinations of multiple factors such as genes and BM microenvironment²⁶. Moreover, immune dysfunction plays an important role in the progression of MM⁶. Thus, the signature of genes and proteins are the key targets to prevent the diseases.

To better understand the effects of inhibitors on the MM mouse models, we analyzed a novel MM mouse model that was created by Blood Research Institute, Versiti. This model was based on the conditionally activating expression of endogenous *Nras*Q61R and a MYC transgene in germinal center B cells (VQ mice)⁹. Thus, by using this transgenic mouse we could produce more MM models to test the drugs and inhibitors as previously described¹⁷. By analyzing the DEGs of this model, we selected 10 proteins that may be important during the development of MM according to the PPI network analysis. G proteins and RGS proteins are widely involved in the immune and inflammatory diseases. In our study, the Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-T2 is a potential prognostic marker of esophageal cancer²⁷. The FOXP3 in T-cells can suppress antigen priming of lymphocytes and can be regulated by the multifunctional circadian clocks²⁸⁻³⁰. CD3g deletion from a consanguineous family is associated with autoimmunity³¹. H2-Ab1 and H2-Eb2 are reported to be involved in the control of tuberculosis infection³². G-protein-coupled receptor (GPCR) proteins and RGS proteins are highly related to the tumor genesis³³⁻³⁶. F2RI2 is recently reported to be a GPCR that encodes protease-activated receptor-3 (PAR3)³⁷. Circadian clock controls numerous genes to regulate the cell functions during normal conditions and diseases^{29, 38-41}. As a clock-controlled gene, CCR5 is reported to suppress anti-tumor immune response and promote tumor growth^{42, 43}. Long and short isoforms of CEACAM1 are strongly expressed on cancer cells in the liver metastases⁴⁴. VAV3 is associated with the ERBB4-mediated cancer cell migration⁴⁵. LAT-1 is identified as a promotor in gastric cancer that is related to the clinicopathologic features⁴⁶.

KEGG and GO analysis showed that immune responses play a critical role in the progression of MM. The KEGG analysis showed the “Natural killer cell mediated cytotoxicity”, “T cell receptor signaling pathway”, “Fc epsilon RI signaling pathway” and “Inflammatory bowel disease (IBD)” were the major pathways during the development of MM. It is suggested that the occurrence of MM is based on the inflammation or immune changes. Similarly, MM is reported to be caused by the disrupted immune surveillance such as deregulation of the T and natural killer cell compartment and recruitment of immunosuppressive cells⁴⁷. Interestingly, the BP of GO analysis showed “Negative

regulation of IL10 production”, “Negative regulation of T cell proliferation” and “B cell activation”, suggesting that the multiple immune cells were involved in the progression of MM not only B cells. Thus, the BM microenvironmental condition is crucial in MM. Indeed, the MM cells disseminate in the BM microenvironment via interactions of the adhesion molecules and extracellular matrix (ECM) components and receive various signals that maintain their survival and activity⁴⁸.

Despite recent advancements in drug development, the anti-cancer drug resistance is a major limitation of MM therapy. Thus, the potential inhibitors may be a good substitute for the traditional drugs of MM. In our study, we predicted several inhibitors of MM that most of them are involved in the regulation of immune and protein synthesis pathways such as NF- κ B pathways. NF- κ B pathway is a center of inflammation which is widely associated in the regulations and controls of diseases^{36, 49}. However, the side effect of NF- κ B inhibitors is so strong that they cannot be used in clinical⁵⁰. Here, besides NF- κ B inhibitors, we selected several novel inhibitors that may take effects on the MM mouse models. Our future studies will mainly target the effects on the treatment of MM by using MM mouse models or primary MM cells.

In summary, we identified the potential biomarkers for MM. Immune dysfunction and BM microenvironment are two key processes in the novel MM mouse models. Future studies will focus on the administration of potential inhibitors on clinical trials. This study thus provides further insights into the mechanism of MM, which may facilitate the diagnosis and drug development.

Reference

- [1] Al-Farsi K: Multiple myeloma: an update. *Oman Med J* 2013, 28:3-11.
- [2] Rajkumar SV: Multiple myeloma. *Curr Probl Cancer* 2009, 33:7-64.
- [3] Hussain A, Almenfi HF, Almeshdewi AM, Hamza MS, Bhat MS, Vijayashankar NP: Laboratory Features of Newly Diagnosed Multiple Myeloma Patients. *Cureus* 2019, 11:e4716.
- [4] Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. *Am J Hematol* 2018, 93:981-1114.
- [5] Chin L, Garraway LA, Fisher DE: Malignant melanoma: genetics and therapeutics in the genomic era. *Genes Dev* 2006, 20:2149-82.
- [6] Romano A, Conticello C, Cavalli M, Vetro C, La Fauci A, Parrinello NL, Di Raimondo F: Immunological dysregulation in multiple myeloma microenvironment. *Biomed Res Int* 2014, 2014:198539.
- [7] Soekoko CY, Ooi M, de Mel S, Chng WJ: Immunotherapy in Multiple Myeloma. *Cells* 2020, 9.
- [8] Rossi M, Botta C, Arbitrio M, Grembiale RD, Tagliaferri P, Tassone P: Mouse models of multiple myeloma: technologic platforms and perspectives. *Oncotarget* 2018, 9:20119-33.
- [9] Wen Z, Rajagopalan A, Flietner ED, Yun G, Chesi M, Furumo Q, Burns RT, Papadas A, Ranheim EA, Pagenkopf AC, Morrow ZT, Finn R, Zhou Y, Li S, You X, Jensen J, Yu M, Cicala A, Menting J, Mitsiades CS, Callander NS, Bergsagel PL, Wang D, Asimakopoulos F, Zhang J: Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice. *Blood* 2021, 137:61-74.
- [10] Fairfield H, Falank C, Avery L, Reagan MR: Multiple myeloma in the marrow: pathogenesis and treatments. *Ann N Y Acad Sci* 2016, 1364:32-51.
- [11] Ghobrial IM: Myeloma as a model for the process of metastasis: implications for therapy. *Blood* 2012, 120:20-30.
- [12] Gu H, Yuan G: Identification of key genes in SARS-CoV-2 patients on bioinformatics analysis. *bioRxiv* 2020:2020.08.09.243444.
- [13] Hanming G, Wei W, Gongsheng Y: Research Square 2020.
- [14] Pomaznoy M, Ha B, Peters B: GOnet: a tool for interactive Gene Ontology analysis. *BMC Bioinformatics* 2018, 19:470.
- [15] Kanehisa M, Goto S: KEGG: kyoto encyclopedia of genes and genomes. *Nucleic Acids Res* 2000, 28:27-30.
- [16] Gu H, Yuan G: Identification of potential key genes for SARS-CoV-2 infected human bronchial organoids based on bioinformatics analysis. *bioRxiv* 2020:2020.08.18.256735.
- [17] Gu H, Yuan G: Identification of potential biomarkers and inhibitors for SARS-CoV-2 infection. *medRxiv* 2020:2020.09.15.20195487.
- [18] Li M, Li D, Tang Y, Wu F, Wang J: CytoCluster: A Cytoscape Plugin for Cluster Analysis and Visualization of Biological Networks. *Int J Mol Sci* 2017, 18.
- [19] Gu H, Yuan G: Identification of specific biomarkers and pathways in the synovial tissues of patients with osteoarthritis in comparison to rheumatoid arthritis. *bioRxiv* 2020:2020.10.22.340232.
- [20] Roncaglia P, Martone ME, Hill DP, Berardini TZ, Foulger RE, Imam FT, Drabkin H, Mungall CJ, Lomax J: The Gene Ontology (GO) Cellular Component Ontology: integration with SAO (Subcellular Anatomy Ontology) and other recent developments. *J Biomed Semantics* 2013, 4:20.
- [21] Safari-Alighiarloo N, Taghizadeh M, Rezaei-Tavirani M, Goliaei B, Peyvandi AA: Protein-protein interaction networks (PPI) and complex diseases. *Gastroenterol Hepatol Bed Bench* 2014, 7:17-31.
- [22] Hanming G, Gongsheng Y: Research Square 2021.
- [23] Rajkumar SV, Kumar S: Multiple Myeloma: Diagnosis and Treatment. *Mayo Clin Proc* 2016, 91:101-19.

- [24] Hameed A, Brady JJ, Dowling P, Clynes M, O'Gorman P: Bone disease in multiple myeloma: pathophysiology and management. *Cancer Growth Metastasis* 2014, 7:33-42.
- [25] Zingone A, Kuehl WM: Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma. *Semin Hematol* 2011, 48:4-12.
- [26] Korn C, Mendez-Ferrer S: Myeloid malignancies and the microenvironment. *Blood* 2017, 129:811-22.
- [27] Liu GM, Ji X, Lu TC, Duan LW, Jia WY, Liu Y, Sun ML, Luo YG: Comprehensive multi-omics analysis identified core molecular processes in esophageal cancer and revealed GNGT2 as a potential prognostic marker. *World J Gastroenterol* 2019, 25:6890-901.
- [28] Yang G, Zhang H, Liu Y, Feng Y, Luo XQ, Liu ZQ, Geng XR, Wang S, Zheng PY, Feng BS, Liu ZG, Yang PC, Li HB, Wu SD: Alternation of circadian clock modulates forkhead box protein-3 gene transcription in CD4(+) T cells in the intestine. *J Allergy Clin Immunol* 2016, 138:1446-9 e10.
- [29] Yuan G, Xu L, Cai T, Hua B, Sun N, Yan Z, Lu C, Qian R: Clock mutant promotes osteoarthritis by inhibiting the acetylation of NFkappaB. *Osteoarthritis Cartilage* 2019, 27:922-31.
- [30] Yuan G, Hua B, Cai T, Xu L, Li E, Huang Y, Sun N, Yan Z, Lu C, Qian R: Clock mediates liver senescence by controlling ER stress. *Aging* 2017, 9:2647-65.
- [31] Gokturk B, Keles S, Kirac M, Artac H, Tokgoz H, Guner SN, Caliskan U, Caliskaner Z, van der Burg M, van Dongen J, Morgan NV, Reisli I: CD3G gene defects in familial autoimmune thyroiditis. *Scand J Immunol* 2014, 80:354-61.
- [32] Logunova N, Korotetskaya M, Polshakov V, Apt A: The QTL within the H2 Complex Involved in the Control of Tuberculosis Infection in Mice Is the Classical Class II H2-Ab1 Gene. *PLoS Genet* 2015, 11:e1005672.
- [33] Fu C, Yuan G, Yang ST, Zhang D, Yang S: RGS12 Represses Oral Cancer via the Phosphorylation and SUMOylation of PTEN. *J Dent Res* 2020:22034520972095.
- [34] Kimple AJ, Bosch DE, Giguere PM, Siderovski DP: Regulators of G-protein signaling and their Galpha substrates: promises and challenges in their use as drug discovery targets. *Pharmacol Rev* 2011, 63:728-49.
- [35] Yuan G, Yang S, Liu M, Yang S: RGS12 is required for the maintenance of mitochondrial function during skeletal development. *Cell Discov* 2020, 6:59.
- [36] Yuan G, Yang S, Gautam M, Luo W, Yang S: Macrophage regulator of G-protein signaling 12 contributes to inflammatory pain hypersensitivity. *Annals of Translational Medicine* 2021.
- [37] Hanzelmann S, Wang J, Guney E, Tang Y, Zhang E, Axelsson AS, Nenonen H, Salehi AS, Wollheim CB, Zetterberg E, Berntorp E, Costa IG, Castelo R, Rosengren AH: Thrombin stimulates insulin secretion via protease-activated receptor-3. *Islets* 2015, 7:e1118195.
- [38] Yuan G, Hua B, Yang Y, Xu L, Cai T, Sun N, Yan Z, Lu C, Qian R: The Circadian Gene Clock Regulates Bone Formation Via PDIA3. *J Bone Miner Res* 2017, 32:861-71.
- [39] Zhu Z, Hua B, Shang Z, Yuan G, Xu L, Li E, Li X, Sun N, Yan Z, Qian R, Lu C: Altered Clock and Lipid Metabolism-Related Genes in Atherosclerotic Mice Kept with Abnormal Lighting Condition. *Biomed Res Int* 2016, 2016:5438589.
- [40] Cai T, Hua B, Luo D, Xu L, Cheng Q, Yuan G, Yan Z, Sun N, Hua L, Lu C: The circadian protein CLOCK regulates cell metabolism via the mitochondrial carrier SLC25A10. *Biochim Biophys Acta Mol Cell Res* 2019, 1866:1310-21.
- [41] Zhu Z, Hua B, Xu L, Yuan G, Li E, Li X, Sun N, Yan Z, Lu C, Qian R: CLOCK promotes 3T3-L1 cell proliferation via Wnt signaling. *IUBMB Life* 2016, 68:557-68.
- [42] Li BH, Garstka MA, Li ZF: Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor. *Mol Immunol* 2020, 117:201-15.
- [43] Chen X, Hu Q, Zhang K, Teng H, Li M, Li D, Wang J, Du Q, Zhao M: The clock-controlled chemokine contributes to neuroinflammation-induced depression. *FASEB J* 2020, 34:8357-66.

- [44] Yamaguchi S, Yokoyama S, Ueno M, Hayami S, Mitani Y, Takeuchi A, Shively JE, Yamaue H: CEACAM1 is associated with recurrence after hepatectomy for colorectal liver metastasis. *J Surg Res* 2017, 220:353-62.
- [45] Ojala VK, Knittle AM, Kirjalainen P, Merilahti JAM, Kortesoja M, Tvorogov D, Vaparanta K, Lin S, Kast J, Pulliainen AT, Kurppa KJ, Elenius K: The guanine nucleotide exchange factor VAV3 participates in ERBB4-mediated cancer cell migration. *J Biol Chem* 2020, 295:11559-71.
- [46] Wang J, Chen X, Su L, Li P, Liu B, Zhu Z: LAT-1 functions as a promotor in gastric cancer associated with clinicopathologic features. *Biomed Pharmacother* 2013, 67:693-9.
- [47] Rodriguez-Otero P, Paiva B, Engelhardt M, Prosper F, San Miguel JF: Is immunotherapy here to stay in multiple myeloma? *Haematologica* 2017, 102:423-32.
- [48] Robak P, Drozd I, Szemraj J, Robak T: Drug resistance in multiple myeloma. *Cancer Treat Rev* 2018, 70:199-208.
- [49] Yuan G, Yang S, Ng A, Fu C, Oursler MJ, Xing L, Yang S: RGS12 Is a Novel Critical NF-kappaB Activator in Inflammatory Arthritis. *iScience* 2020, 23:101172.
- [50] Ramadass V, Vaiyapuri T, Tergaonkar V: Small Molecule NF-kappaB Pathway Inhibitors in Clinic. *Int J Mol Sci* 2020, 21.

Figure 1. The KEGG pathways, biological process, cellular component, and molecular function terms enriched by the DEGs between WT and MM mouse models. DEGs =differentially expressed genes, KEGG = Kyoto Encyclopedia of Genes and Genomes.

Figure 2. Top two modules from the PPI network between WT and MM mouse models.

Figure 3. The Reactom pathway visualization. Input genes are represented by the top significantly changed genes obtained from the GSE153626 dataset ($P < 0.01$). The yellow color represents the most relevant signaling pathways.

Figure 4. Inhibitor prediction against MM by L1000FDW visualization. Input genes are represented by the significantly changed genes obtained from the GSE153626 dataset. Dots are the Mode of Action (MOA) of the respective drug.

Table 1

Entrez gene	Gene Symble	Fold-change	Regulation
Top 10 down-regulated DEGs in COVID-19			
222	Aldh3b2	-1.932183566	Down
1800	Dpep1	-1.932183566	Down
2529	Fut7	-1.932183566	Down
100628598	Mir5129	-1.932183566	Down
5319	Pla2g1b	-1.932183566	Down
100271841	Uckl1os	-1.932183566	Down
2334	Aff2	-1.928411441	Down
201294	Unc13d	-1.927922234	Down
10924	Smpdl3a	-1.926741966	Down
54627	Map10	-1.925629606	Down
Top 10 up-regulated DEGs in COVID-19			
114987	Wdr31	1.8938373435	up
115487260	LOC115487260	1.8192560767	up
84254	Camkk1	1.8173764446	up
90407	Tmem41a	1.8149963395	up
8624	Psmg1	1.8132514217	up
1807	Dpys	1.8100396352	up
147015	Dhrs13	1.8079677725	up
4282	Mif	1.8068839504	up
115485822	LOC115485822	1.8050434401	up
55810	Gm16853	1.7967290544	up

Table 2. Top ten genes demonstrated by connectivity degree in the PPI network

Gene Symbol	Gene title	Degree
Gngt2	G protein subunit gamma transducin 2	15
Foxp3	Forkhead box P3	12
Cd3g	CD3g molecule	10
H2-Ab1	Histocompatibility 2, class II antigen Ab1	9
H2-Eb2	Histocompatibility 2, class II antigen Eb2	8
F2rl2	Coagulation factor II thrombin receptor like 2	8
Ccr5	C-C motif chemokine receptor 5	7
Ceacam1	CEA cell adhesion molecule 1	7
Vav3	Vav guanine nucleotide exchange factor 3	7
Lat	Linker for activation of T cells	7